(2020) The effects of nano-curcumin supplementation on Th1/Th17 balance in migraine patients: A randomized controlled clinical trial. Complementary Therapies in Clinical Practice. ISSN 1744-3881
Full text not available from this repository.
Abstract
Background: The present study was aimed to evaluate the nano-curcumin supplementation on Th1/Th17 balance by assessment of gene expression and serum level of interferon gamma (IFN-gamma) and interleukin-17 (IL-17) in migraine patients. Methods: Forty participants with episodic migraine were randomly allocated to receive 80 mg nano-curcumin (n = 20) or placebo (n = 20) in a randomized double-blind clinical trial for two months. The expression of IFN-gamma and IL-17 from peripheral blood mononuclear cells and IFN-gamma and IL-17 serum levels were measured, using a real-time PCR and ELISA methods, respectively. Results: Compared to placebo group, two month nano-curcumin supplementation led to a significant reduction in serum levels and expression of IL-17 mRNA (P = 0.006 & 0.04, respectively), while there was no statistical difference regarding serum levels and expression of IFN-gamma mRNA. Conclusion: Nano-curcumin supplementation in migraine patients led to a significant reduction in gene expression and plasma levels of IL-17 compared to control group.
Item Type: | Article |
---|---|
Keywords: | Curcumin Migraine Inflammation IL-17 IFN-g GENE-EXPRESSION BIOAVAILABILITY SYSTEM |
Subjects: | WL Nervous System |
Divisions: | Faculty of Medicine > Department of Basic Science > Immunology Department School of Nutrition and Food Sciences > Department of Clinical Nutrition |
Journal or Publication Title: | Complementary Therapies in Clinical Practice |
Journal Index: | ISI |
Volume: | 41 |
Identification Number: | https://doi.org/10.1016/j.ctcp.2020.101256 |
ISSN: | 1744-3881 |
Depositing User: | Zahra Otroj |
URI: | http://eprints.mui.ac.ir/id/eprint/12405 |
Actions (login required)
View Item |